However, we observed significant differences in expression levels of GAS5 between HNSCC patients and healthy volunteers, as well as between HNSCC patients—locally advanced and recurrent and/or metastatic disease compared to non-cancer. This evidence concerns the gene GAS5 and metastatic neoplasm.